Počet záznamů: 1

Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity

SYSNO ASEP	0367735
Druh ASEP	J - Článek v odborném periodiku
Zařazení RIV	J - Článek v odborném periodiku
Poddruh J	Článek ve WOS
Název	Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity
Tvůrce(i)	Tomala, Jakub (MBU-M)_{RID, ORCID} Chmelová, Helena (MBU-M) Strohalm, Jiří (UMCH-V) Ulbrich, Karel (UMCH-V)_RID Šírová, Milada (MBU-M)_{RID, ORCID} Říhová, Blanka (MBU-M)_RID Kovář, Marek (MBU-M)_{RID, ORCID}
Zdroj.dok.	International Journal of Cancer. - : Wiley - ISSN 0020-7136 Roč. 129, č. 8 (2011), s. 2002-2012
Poč.str.	11 s.
Jazyk dok.	eng - angličtina
Země vyd.	DE - Německo
Klíč. slova	IL-2 immunocomplexes ; NK cells ; HPMA copolymer-bound doxorubicin
Vědní obor RIV	EC - Imunologie
CEP	IAA500200712 GA AV ČR - Akademie věd
	GD310/08/H077 GA ČR - Grantová agentura ČR
	GP301/07/P192 GA ČR - Grantová agentura ČR
	1M0505 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy
CEZ	AV0Z50200510 - MBU-M (2005-2011)
	AV0Z40500505 - UMCH-V (2005-2011)
UT WOS	000294224300022
DOI	10.1002/ijc.25859
Anotace	Interleukin (IL)-2 has been approved for treatment of metastatic renal cancer and malignant melanoma. However, its unfavorable pharmacologic properties, severe side effects and the negative role of IL-2 in maintaining T regulatory cells are severe drawbacks. It has been shown that immunocomplexes of IL-2 and certain anti-IL-2 mAbs possess selective and high stimulatory activity in vivo. Here, we show that IL-2/S4B6 mAb immunocomplexes expand not only CD122high subsets and newly activated CD81 T cells but also natural killer T cells and cd T cells. Further, we demonstrate that natural killer (NK) cells expanded by IL-2/S4B6 mAb immunocomplexes in vivo have high cytolytic activity, which can be further increased by coadministration of IL-12. We also demonstrate that IL-2/S4B6 mAb immunocomplexes possess noticeable antitumor activity in two syngeneic mouse tumor models, namely BCL1 leukemia and B16F10 melanoma, but only if administered early in tumor progression
Pracoviště	Mikrobiologický ústav
Kontakt	Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231
Rok sběru	2012

Počet záznamů: 1